...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation.
【24h】

Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation.

机译:腺苷A1受体拮抗剂与孟鲁司特在气道反应性和炎症上的关系。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Adenosine produces bronchoconstriction in allergic rabbits, primates, and humans by activating adenosine A(1) receptors. Previously, it is reported that a high dose of L-97-1, a water-soluble, small molecule adenosine A(1) receptor antagonist, blocks early and late allergic responses, and bronchial hyper-responsiveness to histamine in a hyper-responsive rabbit model of allergic asthma. Effects of a lower dose of L-97-1 are compared to montelukast, a cysteinyl leukotriene-1 receptor antagonist on early allergic response, late allergic response, bronchial hyper-responsiveness, and inflammatory cells in bronchoalveolar lavage (BAL) fluid following house dust mite administration. Rabbits received intraperitoneal injections of house dust mite extract within 24 h of birth followed by booster house dust mite injections. Hyper-responsive rabbits received aerosolized house dust mite (2500 allergen units), 1 h after intragastric administration of L-97-1 (1 mg/kg) or montelukast (0.15 mg/kg) and lung dynamic compliance was measured for 6 h. Lung dynamic compliance was significantly higher following L-97-1 at all time points and with montelukast at 60-300 min following house dust mite (P<0.05). L-97-1 blocks both early and late allergic responses. Montelukast blocks only the late allergic response. Both L-97-1 and montelukast significantly blocked bronchial hyper-responsiveness at 24 h (P<0.05). Both L-97-1 and montelukast significantly reduced BAL eosinophils at 6 h and neutrophils at 6 and 24 h (P<0.05). L-97-1 significantly reduced BAL lymphocytes at 6 and 24 h (P<0.05). Montelukast significantly reduced BAL macrophages at 6 and 24 h (P<0.05). By blocking both bronchoconstriction and airway inflammation, L-97-1 may be an effective oral anti-asthma treatment.
机译:腺苷通过激活腺苷A(1)受体在过敏兔子,灵长类动物和人类中产生支气管收缩作用。以前,据报道,高剂量的L-97-1是一种水溶性小分子腺苷A(1)受体拮抗剂,可阻断早期和晚期过敏反应,并在高反应性中对组胺产生支气管高反应性。过敏性哮喘的兔子模型。比较低剂量L-97-1与半胱氨酸白三烯-1受体拮抗剂孟鲁司特对房尘后支气管肺泡灌洗(BAL)液中早期过敏反应,晚期过敏反应,支气管高反应性和炎症细胞的作用螨虫管理。兔在出生后24小时内腹腔注射室内尘螨提取物,然后再注射室内尘螨。高反应性兔子在胃内施用L-97-1(1 mg / kg)或孟鲁司特(0.15 mg / kg)1小时后接受雾化的屋尘螨(2500过敏原单位),并测量6小时的肺动力顺应性。 L-97-1后所有时间点的肺动态顺应性均显着较高,孟鲁司特在屋尘螨后60-300分钟时的肺动态顺应性显着更高(P <0.05)。 L-97-1阻断早期和晚期过敏反应。孟鲁司特仅阻断晚期过敏反应。 L-97-1和孟鲁司特均在24 h显着阻断支气管高反应性(P <0.05)。 L-97-1和孟鲁司特均在6 h时显着降低BAL嗜酸性粒细胞,在6和24 h时显着降低中性粒细胞(P <0.05)。 L-97-1在6和24小时显着减少BAL淋巴细胞(P <0.05)。孟鲁司特在6和24小时显着减少BAL巨噬细胞(P <0.05)。通过阻断支气管收缩和气道炎症,L-97-1可能是一种有效的口服抗哮喘治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号